Matthews / Gerritsen Targeting Protein Kinases for Cancer Therapy

1. Auflage 2011
ISBN: 978-1-118-21077-2
Verlag: John Wiley & Sons
Format: EPUB
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 720 Seiten, E-Book

An expert guide to targeting protein kinases in cancertherapy
Research has shown that protein kinases can instigate theformation and spread of cancer when they transmit faulty signalsinside cells. Because of this fact, pharmaceutical scientists havetargeted kinases for intensive study, and have been working todevelop medicinal roadblocks to sever their malignant means ofcommunication.
Complete with full-color presentations, Targeting ProteinKinases for Cancer Therapy defines the structural features ofprotein kinases and examines their cellular functions. Combiningkinase biology with chemistry and pharmacology applications, thisbook enlists emerging data to drive the discovery of newcancer-fighting drugs. Valuable information includes:
* Comprehensive overviews of the major kinase families involved inoncology, integrating protein structure and function, and providingimportant tools to assist pharmaceutical researchers to understandand work in this dynamic area of cancer drug research
* Focus on small molecule inhibitors as well as other therapeuticmodalities
* Discussion of kinase inhibitors that have entered clinicaltrials for the treatment of cancer, with an emphasis on moleculesthat have progressed to late stage clinical trials and, in a fewcases, to market
Providing a platform for further study, this important workreviews both the successes and challenges of kinase inhibitortherapy, and provides insight into future directions in the waragainst cancer.

Autoren/Hrsg.

Matthews, David J.

Gerritsen, Mary E.

Über Autor(innen)

DAVID J. MATTHEWS is Executive Director of OncologyDiscovery at Exelixis, where he is responsible for cancer drugdiscovery. For more than fifteen years, Dr. Matthews has beeninvolved in drug discovery projects in industry, with particularfocus on small molecule inhibitors. He has twenty scientificpublications and multiple patents to his credit.
MARY E. GERRITSEN is Vice President of Molecular andCellular Pharmacology at Exelixis, where she is in charge ofcell-based screening in preclinical research and of biomarkerstudies for clinical development compounds in Phase I and IIstudies. Her prior industry experience includes positions atGenentech, Bayer and Millennium Pharmaceuticals. She has authoredmore than one hundred peer-reviewed articles and twenty-six bookchapters and is an inventor on forty-two issued patents.